National Multicenter Cohort Registry Study of Rapid rEcurrences of Coronary Unexplained In-stent Restenosis

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT05437965

Acronym

RECUR Registry

Enrollment

1000

Registered

2022-06-29

Start date

2020-06-03

Completion date

2035-04-01

Last updated

2025-08-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Arteritis, Coronary Artery Disease, In-Stent Stenosis (Restenosis) of Coronary Artery Stent

Keywords

coronary arteritis, biomarker, inflammation

Brief summary

This project aims to establish a clinical cohort and diagnostic assessment framework by conducting a national multicenter cohort registry study. Through the collection of patients' clinical characteristics, it will achieve the registration, management, follow-up, and analysis of patients with Rapid rEcurrences of Coronary Unexplained in-stent Restenosis (RECUR).

Interventions

OTHERTreatment made by experienced clinicians

Treatment made by experienced clinicians

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

1. Age ≥ 18 years; 2. Patients meeting the diagnostic criteria for Rapid rEcurrences of Coronary Unexplained in-stent Restenosis (RECUR); 3. Patients fully informed about the trial procedures who provide written informed consent.

Exclusion criteria

1. Patients presenting with any of the following: * Other severe comorbidities (e.g., malignant tumors, heart failure) with a life expectancy \<12 months; * Known autoimmune/rheumatic diseases including systemic lupus erythematosus, Takayasu arteritis, Behçet's disease, polyarteritis nodosa, Wegener granulomatosis (granulomatosis with polyangiitis), eosinophilic arteritis, giant cell arteritis, rheumatoid arthritis, or IgG4-related disease; * Variant angina (Prinzmetal's angina); * Coronary artery dissection; * Thrombophilia; * Stent underexpansion. 2. Presence of psychiatric disorders; 3. Known inability to complete expected study follow-up for any reason; 4. Patients deemed ineligible for enrollment by the investigator.

Design outcomes

Primary

Measure	Time frame	Description
Target vessel failure	10 year	Time to the incidence of target vessel failure, a composite of cardiovascular death, target vessel-related myocardial infarction, and target vessel-related revascularization.

Countries

China

Contacts

Primary ContactHong Jian Wang, Dr.

hongjian.wang@gmail.com008613910008985

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Jul 3, 2026